NEW YORK (GenomeWeb) – CareDx announced this week that it has closed its acquisition of Allenex. The acquisition included a successful tender of 98.37 percent of Allenex shares as part of a public tender offer concluded in Sweden, the company said. CareDx will be able to buy out the remaining shares on a compulsory basis. The company said last week that Allenex shareholders representing about 98 percent of the company's shares had accepted CareDx's takeover offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.